Previous Article | Next Article ![]()
Journal of Virology, March 2000, p. 2178-2185, Vol. 74, No. 5
Viral Immunology
Section1 and Core DNA Sequencing
Facility,4 National Institute of Neurological
Disorders and Stroke, Howard Hughes Medical Institute
Received 3 June 1999/Accepted 23 November 1999
Serological screening for human T-lymphotropic virus type 1 (HTLV-1) parallels the standard screening process for human
immunodeficiency virus (HIV), in which samples found positive by
enzyme-linked immunosorbent assay (ELISA) are confirmed with a modified
Western blot procedure. There are a significant number of cases in
which HTLV-1/2 ELISA-positive specimens demonstrate an incomplete
banding pattern on this Western blot. Individuals providing these
atypical antibody responses are categorized as seroindeterminate for
HTLV-1/2. Although HTLV-1 genomic sequences are readily detectable in
the peripheral blood lymphocytes (PBL) of seropositive individuals, previous studies have repeatedly demonstrated that PBL from the vast
majority of HTLV-1/2 seroindeterminate individuals are PCR negative for
HTLV-1. As a result, identification of the agent responsible for this
indeterminate reactivity has been of interest. We have generated an
HTLV-1-positive B-cell line (SI-1 B) from one of these
seroindeterminate individuals. Previous screening for HTLV-1 in PBL
from this patient had been routinely negative by primary PCR; however,
HTLV-1 tax had been periodically detected by nested PCR.
DNA sequence data generated with genomic DNA from the SI-1 B cell line
and HTLV-1-specific primers demonstrated the presence of a full-length
viral genome with >97% homology to the Cosmopolitan form of HTLV-1. A
12-bp deletion was identified in the
3'-gag/5'-prot region, which would predict
translation of altered or nonfunctional proteins from these genes. We
propose that this HTLV-1/2-seroindeterminate patient is infected with a
prototypic form of HTLV-1 at an extremely low viral load and that this
finding may explain HTLV-1/2 seroindeterminate reactivity in at least a
subset of these individuals.
0022-538X/00/$04.00+0
Characterization and Sequencing of Prototypic
Human T-Lymphotropic Virus Type 1 (HTLV-1) from an HTLV-1/2
Seroindeterminate Patient
National
Institutes of Health Research Scholars Program, Bethesda, Maryland
20892,2 and Institute for Biomedical
Sciences, Department of Genetics, George Washington University,
Washington, D.C. 200523
*
Corresponding author. Mailing address: Viral Immunology
Section, National Institute of Neurological Disorders and Stroke, 9000 Rockville Pike, Room 5B-16, Bethesda, MD 20892. Phone: (301) 496-0519. Fax: (301) 402-0373. E-mail: stevej{at}helix.nih.gov.
This article has been cited by other articles:
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|